The estimated Net Worth of Michael S Perry is at least $14.8 Million dollars as of 21 November 2022. Dr Perry owns over 150,000 units of AVITA Medical Inc stock worth over $3,632,227 and over the last 13 years he sold RCEL stock worth over $10,060,240. In addition, he makes $1,058,847 as CEO und Pres & Exec. Director at AVITA Medical Inc.
Dr has made over 11 trades of the AVITA Medical Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of RCEL stock worth $898,500 on 21 November 2022.
The largest trade he's ever made was selling 185,000 units of AVITA Medical Inc stock on 9 September 2019 worth over $5,440,850. On average, Dr trades about 17,470 units every 35 days since 2012. As of 21 November 2022 he still owns at least 379,543 units of AVITA Medical Inc stock.
You can see the complete history of Dr Perry stock trades at the bottom of the page.
Dr. Michael S. Perry D.V.M., DVM, FACVPT, Ph.D. is the CEO, Pres & Exec. Director at AVITA Medical Inc.
As the CEO und Pres & Exec. Director of AVITA Medical Inc, the total compensation of Dr D at AVITA Medical Inc is $1,058,847. There are no executives at AVITA Medical Inc getting paid more.
Dr D is 62, he's been the CEO und Pres & Exec. Director of AVITA Medical Inc since . There are no older and 5 younger executives at AVITA Medical Inc.
Michael's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 5 years, insiders at AVITA Medical Inc have traded over $2,850,472 worth of AVITA Medical Inc stock and bought 19,459 units worth $293,310 . The most active insiders traders include Michael S Perry, James Corbett und David D O'toole. On average, AVITA Medical Inc executives and independent directors trade stock every 82 days with the average trade being worth of $135,636. The most recent stock trade was executed by David D O'toole on 30 May 2024, trading 1,000 units of RCEL stock currently worth $8,900.
avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.
AVITA Medical Inc executives and other stock owners filed with the SEC include: